<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of the Securities
Exchange Act of 1934 (Amendment No. )
Filed by the Registrant [X]
Filed by a Party other than the Registrant [_]
Check the appropriate box:
[_] Preliminary Proxy Statement [_] CONFIDENTIAL, FOR USE OF THE
COMMISSION ONLY (AS PERMITTED BY
RULE 14A-6(E)(2))
[X] Definitive Proxy Statement
[_] Definitive Additional Materials
[_] Soliciting Material Pursuant to Section 240.14a-11(c) or Section 240.14a-12
SYNETIC, INC.
- - --------------------------------------------------------------------------------
(Name of Registrant as Specified In Its Charter)
- - --------------------------------------------------------------------------------
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
[X] No fee required
[_] Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.
(1) Title of each class of securities to which transaction applies:
-------------------------------------------------------------------------
(2) Aggregate number of securities to which transaction applies:
-------------------------------------------------------------------------
(3) Per unit price or other underlying value of transaction computed
pursuant to Exchange Act Rule 0-11 (Set forth the amount on which
the filing fee is calculated and state how it was determined):
-------------------------------------------------------------------------
(4) Proposed maximum aggregate value of transaction:
-------------------------------------------------------------------------
(5) Total fee paid:
-------------------------------------------------------------------------
[_] Fee paid previously with preliminary materials.
[_] Check box if any part of the fee is offset as provided by Exchange
Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee
was paid previously. Identify the previous filing by registration statement
number, or the Form or Schedule and the date of its filing.
(1) Amount Previously Paid:
-------------------------------------------------------------------------
(2) Form, Schedule or Registration Statement No.:
-------------------------------------------------------------------------
(3) Filing Party:
-------------------------------------------------------------------------
(4) Date Filed:
-------------------------------------------------------------------------
Notes:
<PAGE>
[SYNETIC LOGO]
SYNETIC, INC.
669 River Drive
Elmwood Park, New Jersey 07407-1361
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD APRIL 16, 1999
NOTICE IS HEREBY GIVEN that the Annual Meeting of Stockholders (the
"Meeting") of Synetic, Inc. (the "Company") will be held at 9:30 A.M., local
time, on Friday, April 16, 1999, at the St. Regis Hotel, Two East 55th Street,
Versailles Room, New York, New York 10022, for the following purposes:
1. To elect eleven members to the Company's Board of Directors.
2. To ratify the appointment of Arthur Andersen LLP as independent
auditors of the Company for the fiscal year ending June 30, 1999.
3. To consider and transact such other business as may properly be
brought before the Meeting or any adjournment or postponement thereof.
Only stockholders of record at the close of business on March 5, 1999 will
be entitled to vote at the Meeting. The stock transfer books will not be
closed.
By Order of the Board of Directors,
Charles A. Mele
Secretary
Elmwood Park, New Jersey
March 12, 1999
____________________________
A proxy card and the Annual Report of the Company for the fiscal year ended June
30, 1998 are enclosed.
<PAGE>
YOUR VOTE IS IMPORTANT
To ensure that your interests will be represented at the Meeting, whether
or not you plan to attend the Meeting, please complete, date, sign and mail your
proxy promptly in the enclosed postage-paid envelope. Stockholders who attend
the Meeting in person may revoke their proxies and vote in person if they
desire.
FORWARD-LOOKING INFORMATION
This Proxy Statement contains certain forward-looking statements and
information relating to the Company and its operations, governance and policies
and procedures that are based on the beliefs of the Company's management as well
as assumptions made by and information currently available to the Company's
management. When used in this Proxy Statement, the words "anticipate",
"believe", "estimate", "expect" and similar expressions, as they relate to the
Company or the Company's management, are intended to identify forward-looking
statements. Such statements reflect the current view of the Company with
respect to future events and are subject to certain risks, uncertainties and
assumptions, including, but not limited to, risks and uncertainties associated
with the interpretation of the non-competition agreements and related litigation
referred to herein. Should one or more of these risks or uncertainties
materialize, or should underlying assumptions prove incorrect, actual results
may vary materially from those described herein as anticipated, believed,
estimated or expected. Further information about these matters can be found in
the Company's other Securities and Exchange Commission filings. The Company
does not intend to update these forward-looking statements.
<PAGE>
SYNETIC, INC.
669 River Drive
Elmwood Park, New Jersey 07407-1361
PROXY STATEMENT
ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD ON APRIL 16, 1999
This Proxy Statement and the enclosed form of proxy are furnished to
stockholders of Synetic, Inc., a Delaware corporation (the "Company"), in
connection with the solicitation of proxies by the Board of Directors of the
Company from holders of outstanding shares of its common stock, par value $.01
per share ("Common Stock"), for use at the Annual Meeting of Stockholders (the
"Meeting") to be held on Friday, April 16, 1999 and at any adjournment or
postponement thereof. The approximate date on which this Proxy Statement and
the related form of proxy are first being sent to stockholders is March 12,
1999.
If the enclosed proxy is properly signed and returned, and if the
stockholder specifies a choice on the proxy, the shares of Common Stock
represented by the proxy will be voted (or withheld from voting) in accordance
with the stockholder's choice. If the proxy is signed and returned but no
specification is made, the proxy will be voted as follows:
. FOR the election of each of the nominees for director listed below
("Proposal One"); and
. FOR the proposal ("Proposal Two") to ratify the appointment of
independent auditors.
The Board of Directors of the Company (the "Board") knows of no business
that will be presented for consideration at the Meeting other than the matters
described in this Proxy Statement. If any other matters are presented at the
Meeting, the proxy holders will vote the proxies in accordance with their
judgment.
Any proxy may be revoked by the stockholder giving it, at any time prior to
its being voted, by filing with the Secretary of the Company at its address set
forth above, a notice of revocation or a duly executed proxy bearing a later
date. Any proxy may also be revoked by the stockholder's attendance at the
Meeting and voting in person. A notice of revocation need not be on any specific
form.
This solicitation is being made on behalf of the Board, and its cost
(including preparing and mailing of the notice, this Proxy Statement and the
form of proxy) will be paid by the Company. The Company will also make
arrangements with brokerage houses and other custodians, nominees and
fiduciaries to send the proxy materials to their principals and will reimburse
them for their reasonable expenses in so doing. To the extent necessary in order
to ensure sufficient representation at the Meeting, officers and regular
employees of the Company may solicit the return of proxies by mail, telephone,
telegram, telex and personal interview. No compensation in addition to regular
salary and benefits will be paid to any officer or regular employee for such
solicitation. In addition, the Company has retained Innisfree M&A Incorporated
to assist in the solicitation of proxies from beneficial owners of shares held
of record by brokerage houses, banks and other custodians, nominees or
fiduciaries, at a cost not to exceed $6,500 plus reasonable out-of-pocket
expenses.
1
<PAGE>
RECORD DATE AND VOTING AT THE MEETING
The Board has fixed the close of business on March 5, 1999 as the record
date (the "Record Date") for the determination of the stockholders of the
Company entitled to notice of, and to vote at, the Meeting. At that date, there
were outstanding 20,418,143 shares of Common Stock, the holders of which will be
entitled to one vote per share on each matter submitted to the Meeting. See
"Proposal One: Election of Directors". No other voting securities of the
Company are outstanding.
The presence at the Meeting, in person or by proxy, of the holders of a
majority of the shares entitled to vote at the Meeting constitutes a quorum for
the transaction of business at the Meeting. If a quorum should not be present,
the Meeting may be adjourned from time to time until a quorum is obtained.
Shares of Common Stock present in person or represented by proxy (including
shares which abstain or do not vote with respect to one or more matters
presented for stockholder approval) will be counted for purposes of determining
whether a quorum exists at the Meeting.
The following considerations apply to the voting of stockholders with
respect to each of the respective proposals:
. Proposal One: Election of Directors. Under the By-laws of the Company
("By-laws"), the eleven nominees receiving the greatest number of
votes cast shall be elected directors of the Company. Only votes cast
FOR a nominee will be counted. Abstentions, broker non-votes and
instructions on the accompanying proxy card to withhold authority to
vote for one or more of the nominees will result in the respective
nominees receiving fewer votes.
. Proposal Two: Ratification of Independent Auditors. The affirmative
vote of the holders of a majority of the votes cast at the Meeting is
required to ratify the appointment of Arthur Andersen LLP as the
Company's independent auditors. Abstentions and broker non-votes with
respect to Proposal Two will not be considered as votes cast and,
accordingly, will have no effect on the outcome of the vote with
respect to Proposal Two.
2
<PAGE>
PRINCIPAL STOCKHOLDERS
The following table sets forth certain information as of March 3, 1999
(except as otherwise indicated) concerning the beneficial ownership of the
Company's Common Stock by each person known by the Company to own more than 5%
of its Common Stock.
<TABLE>
<CAPTION>
Amount
Name and Address of and Nature of Percent
Beneficial Owner Beneficial Ownership of Class (1)
- - ------------------------------------ ------------------------ ------------
<S> <C> <C>
Martin J. Wygod............................. 5,379,948(2)(3) 26.2%
c/o Synetic, Inc.
669 River Drive, Center 2,
Elmwood Park, NJ 07407
SN Investors, L.P........................... 5,061,857(2) 24.9%
818 Washington Street
Wilmington, Delaware 19801
The Prudential Insurance Company............ 1,329,494(4) 6.5%
of America
Prudential Plaza
Newark, New Jersey 07102
FMR Corp.................................... 1,157,582(5) 5.7%
82 Devonshire Street
Boston, Massachusetts 02107
</TABLE>
- - -------------------------------------
(1) The number of shares of Common Stock deemed outstanding includes: (i)
20,337,143 shares of Common Stock outstanding as of March 3, 1999, (ii) the
number of shares, if any, of Common Stock that the respective persons named
in the above table have the right to acquire presently or within 60 days of
March 3, 1999 upon exercise of stock options and (iii) the number of shares,
if any, of Common Stock, which the respective persons named in the above
table have the right to acquire upon conversion of the Company's 5%
Convertible Subordinated Debentures due 2007 ("Convertible Debentures").
(2) SN Investors, L.P. ("SN Investors"), a limited partnership the general
partner of which is SYNC, Inc. (the "General Partner"), whose sole
stockholder is Mr. Wygod, Chairman of the Board of the Company, is the
record and beneficial owner of 5,061,857 shares of Common Stock. Mr. Wygod
is an indirect beneficial owner of such shares and they are included in the
total of 5,379,948 shares listed as beneficially owned by Mr. Wygod. See
"Certain Relationships and Related Transactions-Investment Agreement" for
additional information regarding SN Investors.
(3) Includes 212,000 shares of Common Stock that Mr. Wygod has the right to
acquire presently or within 60 days of March 3, 1999 upon exercise of stock
options and upon conversion of Convertible Debentures. Includes 2,000
shares of Common Stock beneficially owned by Mr. Wygod's spouse, as to which
shares Mr. Wygod disclaims beneficial ownership. Does not include 3,500
shares of Common Stock and shares of Common Stock issuable upon conversion
of $1,500,000 principal amount of Convertible Debentures owned by Synetic
Foundation, Inc., formerly known as the Medco Containment Services
Foundation, Inc. ("Synetic Foundation"), a charitable foundation of which
Messrs. Manning, Suthern and Wygod are trustees and share voting and
3
<PAGE>
dispositive power, nor 186,961 shares of Common Stock and shares of Common
Stock issuable upon conversion of $500,000 principal amount of Convertible
Debentures owned by the Rose Foundation ("Rose Foundation"), a private
charitable foundation of which Messrs. Wygod and Mele are trustees and share
voting and dispositive power.
(4) Includes 117,333 shares of Common Stock that The Prudential Insurance
Company of America ("Prudential") has the right to acquire upon conversion
of Convertible Debentures. The information shown is as of December 31, 1998
and is based upon information disclosed by Prudential in its Schedule 13G
filed with the Securities and Exchange Commission (the "Commission").
Prudential reported in its Schedule 13G that it has shared voting and
dispositive power over such shares.
(5) The information shown is as of December 31, 1998 and is based upon
information disclosed by FMR Corp., Fidelity Management and Research
Company, Fidelity VIP Equity-Income Fund, Abigail P. Johnson and Edward C.
Johnson, 3d, the controlling stockholder of FMR Corp., in a Schedule 13G
filed with the Commission. Such persons reported that FMR Corp. is the
parent holding company of Fidelity Management and Research Company, and that
Edward C. Johnson, 3d, FMR Corp., through its control of Fidelity Management
and Research Company, and the Fund each has sole power to dispose of such
shares. Sole power to vote the shares resides in the Fund's Board of
Trustees.
4
<PAGE>
SECURITY OWNERSHIP OF MANAGEMENT
The following table sets forth certain information, as of March 3, 1999,
concerning the ownership of Common Stock by each of the directors, each of the
Named Executive Officers, and by all directors and executive officers of the
Company as a group.
<TABLE>
<CAPTION>
Amount and
Nature of Beneficial Percent of
Name of Beneficial Owner Ownership (1)(2) Class (3)
- - -------------------------------------------------- -------------------------- ---------------
<S> <C> <C>
Thomas R. Ferguson............................................. 116,116 *
Mervyn L. Goldstein............................................ 114,716(4) *
Ray E. Hannah.................................................. 138,980 *
Roger H. Licht................................................. 74,333 *
James V. Manning............................................... 274,799(5) 1.34%
Bernard A. Marden.............................................. 352,003(11) 1.72%
David M. Margulies............................................. 28,917 *
Charles A. Mele................................................ 153,084(6) *
Herman Sarkowsky............................................... 219,338(7) 1.07%
Paul C. Suthern................................................ 311,798(5)(10) 1.51%
Anthony Vuolo.................................................. 177,323 *
Albert M. Weis................................................. 160,488(8) *
Martin J. Wygod................................................ 5,379,948(5)(6)(9) 26.18%
All directors and executive officers
as a group (17 persons)...................................... 7,741,229 35.07%
</TABLE>
- - --------------------------------
* Less than one percent.
(1) The persons named in the table have sole voting and investment power with
respect to all shares of Common Stock shown as beneficially owned by them,
unless otherwise indicated in the following footnotes.
(2) Includes the following number of shares of Common Stock that the following
persons have the right to acquire presently or within 60 days of March 3,
1999 upon exercise of stock options and the number of shares of Common
Stock that the following persons have the right to acquire upon conversion
of Convertible Debentures: Mr. Ferguson, 71,666; Dr. Goldstein, 71,666;
Mr. Hannah, 46,166; Mr. Licht, 70,333; Mr. Manning, 168,333; Mr. Marden,
85,335; Mr. Mele, 125,833; Mr. Sarkowsky, 94,999; Mr. Suthern, 305,300; Mr.
Vuolo, 173,233; Mr. Weis, 74,166; Mr. Wygod, 212,000; and all directors and
executive officers as a group, 1,737,863. Also includes 1,508 shares of
Common Stock allocated to the account of Mr. Hannah, 194 shares of Common
Stock allocated to the account of Mr. Mele and 189 shares of Common Stock
allocated to the account of Mr. Vuolo under the Porex 401(k) Plan as of
September 30, 1998.
(3) The number of shares of Common Stock deemed outstanding includes: (i)
20,337,143 shares of Common Stock outstanding as of March 3, 1999, (ii) the
number of shares of Common Stock that the respective persons named in the
above table have the right to acquire presently or within 60 days of March
3, 1999 upon exercise of stock options and (iii) the number of shares of
Common Stock that the respective persons named in the above table have the
right to acquire upon conversion of Convertible Debentures.
(4) Includes 200 shares of Common Stock owned by Dr. Goldstein's spouse, as to
which Dr. Goldstein disclaims beneficial ownership.
5
<PAGE>
(5) Does not include 3,500 shares of Common Stock and shares of Common Stock
issuable upon conversion of $1,500,000 principal amount of Convertible
Debentures owned by Synetic Foundation, a charitable foundation of which
Messrs. Manning, Suthern and Wygod are trustees and share voting and
dispositive power.
(6) Does not include 186,961 shares of Common Stock and shares of Common Stock
issuable upon conversion of $500,000 principal amount of Convertible
Debentures owned by the Rose Foundation, a private charitable foundation of
which Messrs. Mele and Wygod are trustees and share voting and dispositive
power.
(7) Includes shares of Common Stock issuable upon conversion of $1,500,000
principal amount of Convertible Debentures owned by the Sarkowsky Family
Limited Partnership, the general partner of which is controlled by Mr.
Sarkowsky. Does not include shares of Common Stock owned by a charitable
foundation of which Mr. Sarkowsky is a director.
(8) Includes 4,450 shares of Common Stock owned by a corporation of which Mr.
Weis is the sole stockholder, sole director and president and 3,200 shares
of Common Stock held in trust for Mr. Weis' children.
(9) Includes 2,000 shares of Common Stock beneficially owned by Mr. Wygod's
spouse, as to which shares Mr. Wygod disclaims beneficial ownership.
(10) Includes 1,200 shares of Common Stock held in custodial accounts for Mr.
Suthern's children.
(11) Does not include shares of Common Stock owned by a charitable foundation.
6
<PAGE>
PROPOSAL ONE:
ELECTION OF DIRECTORS
The proxy will be voted in accordance with the directions thereon with
respect to Proposal One, or, if no directions are given, FOR the election of the
eleven nominees for director described below, each of whom is currently serving
as a director.
The holders of Common Stock are being asked to elect eleven members to the
Board. The eleven members who are so elected will be directors of the Company.
During the fiscal year ended June 30, 1998, the Board had four standing
committees: an Audit Committee, a Stock Option Committee, a Compensation
Committee and an Executive Committee. The Audit Committee is responsible for
reviewing the internal accounting controls and procedures of the Company with
management and the independent auditors, accounting principles, related party
transactions and the scope of the annual audit of the Company. The Stock Option
Committee administers the Company's stock option plans. The Board has delegated
to the Executive Committee the power to exercise, to the fullest extent
permitted by law, the powers of the entire Board. The Compensation Committee is
responsible for reviewing and approving compensation levels for the Company's
executive officers and reviewing and making recommendations to the Board with
respect to other matters relating to the compensation practices of the Company.
The Board has no nominating committee. The entire Board performs those
functions often performed by a nominating committee.
During the fiscal year ended June 30, 1998, the Board of the Company held
six meetings and also took certain actions by written consent. The Stock Option
Committee held no formal meetings during such period, but took certain actions
by written consent. The Audit Committee held three meetings. The Executive
Committee held no formal meetings during such period, but took certain actions
by written consent. Each director attended more than 75% of the Board meetings
and the meetings of Board committees on which he served.
Under the Company's By-laws, the nominees receiving the greatest number of
votes cast shall be elected directors of the Company.
Messrs. Ferguson, Goldstein, Hannah, Licht, Manning, Marden, Mele,
Sarkowsky, Suthern, Weis and Wygod are the nominees, selected by the Board, for
election to serve one-year terms expiring at the next Annual Meeting of
Stockholders of the Company.
If for any reason any nominee for director should become unavailable for
election, the proxies may be voted for the election of a substitute designated
by management, unless a contrary instruction is given on the proxy. Management
has no reason to believe that any of the nominees will be unable or unwilling to
serve if elected, and all nominees have expressed an intention to serve the
entire term for which election is sought.
7
<PAGE>
NOMINEES FOR ELECTION TO THE BOARD OF DIRECTORS
Certain information as of March 3, 1999 concerning the nominees is set
forth below:
<TABLE>
<CAPTION>
Name Age Director Since
- - ------------------------------------------------------ ------- ------------------
<S> <C> <C>
Thomas R. Ferguson(A)(B)(C)(D) 72 1989
Mervyn L. Goldstein, M.D. 61 1989
Ray E. Hannah 63 1989
Roger H. Licht 45 1989
James V. Manning(D) 52 1989
Bernard A. Marden 79 1997
Charles A. Mele 42 1989
Herman Sarkowsky(A)(B)(C) 73 1989
Paul C. Suthern 47 1993
Albert M. Weis(A)(B)(C)(D) 72 1989
Martin J. Wygod 59 1989
</TABLE>
- - ---------------
(A) Member of the Audit Committee.
(B) Member of the Stock Option Committee.
(C) Member of the Compensation Committee.
(D) Member of the Executive Committee.
--------------------
Mr. Ferguson has been a member of the law firm of Ferguson, Case, Orr,
Paterson & Cunningham for more than five years.
Dr. Goldstein has been a physician in private practice, Associate Clinical
Professor of Medicine at the Albert Einstein College of Medicine in New York
City and Attending Physician in Medicine and Oncology at Montefiore Medical
Center in New York City for more than five years.
Mr. Hannah has been Co-Chairman of Porex Technologies Corp. ("Porex") since
January 1998 and was President of Porex from September 1987 to December 1997 and
its Chief Executive Officer from November 1992 to December 1997 and an executive
officer of the Company from June 1989 to June 30, 1998. Mr. Hannah was the
Chief Operating Officer of Porex from November 1984 to November 1992.
Mr. Licht has been a member of the law firm of Licht & Licht for more than
five years. On February 17, 1999, Mr. Licht reached a settlement regarding an
action by the Commission pursuant to which Mr. Licht agreed, without admitting
or denying any of the allegations in the Commission's action, to the entry of a
permanent injunction prohibiting him from any future violations of the federal
securities laws.
8
<PAGE>
Mr. Manning has been Vice Chairman since March 1998 and was Chief Executive
Officer of the Company from January 1995 to March 1998 and President of the
Company from July 1996 to March 1998. Mr. Manning was, until March 1998, an
executive officer of the Company for more than the last five years and was,
until December 1994, an executive officer of Medco Containment Services, Inc.
("Medco") for more than five years. He is also Chairman of the Board of Group 1
Software, Inc., a computer software company.
Mr. Marden has been a private investor for more than five years.
Mr. Mele has been Executive Vice President-General Counsel of the Company
since March 1998 and was Vice President-General Counsel from July 1995 to March
1998. Mr. Mele was an executive officer of the Company from May 1989 until
December 1994 and was an executive officer of Medco for more than five years,
until March 1995. Mr. Mele is also a director of Comnet Corporation and Group 1
Software, Inc., a computer software company.
Mr. Sarkowsky has been Chairman of the Board and Chief Executive Officer of
Sarkowsky Investment Corporation, a diversified investment company, for more
than five years. From May 1992 to May 1997, he served as a director of Seafirst
Bank. Mr. Sarkowsky is also a director of Eagle Hardware & Garden Inc. and
Hollywood Park, Inc.
Mr. Suthern has been President and Chief Executive Officer of the Company
since March 1998 and was an executive officer of the Company from February 1993
until July 1996, Vice Chairman of the Company from July 1996 to March 1998 and
also chief executive officer from October 1993 until January 1995. Mr. Suthern
was also President and Chief Operating Officer of Medco from November 1992
through December 1994 and Assistant to Medco's Chairman from December 1991 to
November 1992. Prior thereto, he was Executive Vice President-Operations of
Medco for more than five years.
Mr. Weis has been President of A.M. Weis & Co., Inc., a commodities trading
corporation, for more than five years. Since August 1997, Mr. Weis has been the
Chairman of the Board of the New York Cotton Exchange. Mr. Weis is also a
member of the Board of the Commodities Clearing Corporation.
Mr. Wygod has been Chairman of the Board of the Company since May 1989.
From May 1989 to February 1993, Mr. Wygod also served as the Company's President
and Chief Executive Officer and until May 1994 was an executive officer of the
Company. Until May 1994, Mr. Wygod was Chairman of the Board of Medco for more
than five years, and until January 1993 he also served as Chief Executive
Officer of Medco. He is also engaged in the business of racing, boarding and
breeding thoroughbred horses, and is President of River Edge Farm, Inc., which
is engaged in the business of breeding and boarding thoroughbred horses.
No family relationship exists among any of the directors or executive
officers except that Martin J. Wygod, Chairman of the Board of the Company, and
Paul C. Suthern, President and Chief Executive Officer of the Company, are
brothers-in-law. No arrangement or understanding exists between any director or
executive officer and any other person pursuant to which any director or
executive officer was selected as a director or executive officer of the
Company. All executive officers are elected annually by the Board and serve at
the discretion of the Board.
SECTION 16(A) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE
Based solely upon a review of Forms 3 and 4 and amendments thereto
furnished to the Company during the year ended June 30, 1998 and Forms 5 and
amendments thereto furnished to the Company for such year, no person failed to
file on a timely basis, as disclosed in the above forms, reports required by
Section 16(a) of the Securities Exchange Act of 1934, as amended, during such
year, except that a gift made by Bernard Marden to a charitable foundation was
inadvertently filed late due to a clerical error.
9
<PAGE>
EXECUTIVE COMPENSATION
The following table presents information concerning compensation paid for
services to the Company during the last three fiscal years with respect to the
Company's Chief Executive Officer, the Company's former Chief Executive Officer
and the other four most highly compensated executive officers of the Company
(the "Named Executive Officers"):
Summary Compensation Table
<TABLE>
<CAPTION> Long Term
Annual Compensation Compensation
------------------------------------- ---------------
Securities
Underlying All Other
Options/ Compen-
Name and Principal Position Year Salary ($) Bonus($) SARs (#) sation ($)
- - ---------------------------------- ------- --------------- ----------- --------------- -----------------
<S> <C> <C> <C> <C> <C>
James V. Manning.................. 1998 100,000 - - -
President (July 1996 to March 1997 100,000 - - -
1998) and Chief Executive 1996 100,000 - - -
Officer (January 1995 to March
1998)(1)
Paul C. Suthern................... 1998 97,692 - 194,000 -
President (beginning March 1998) 1997 - - - -
& Chief Executive Officer 1996 160,000 - - -
(October 1993 to January 1995
and beginning March 1998)
David M. Margulies................ 1998 175,000 - 272,728(3) -
Executive Vice President 1997 72,019(2) - 272,728(3) -
-Chief Scientist 1996 - - - -
Ray E. Hannah..................... 1998 175,000 - - 3,683(4)
Vice President 1997 163,461 100,000 40,000 5,901(4)
-Porex Technologies Group 1996 160,000 74,140 - 3,239(4)
(through June 1998)
Charles A. Mele................... 1998 159,692 - 85,000 3,163(5)
Executive Vice President and 1997 150,000 - 195,000 2,019(5)
General Counsel 1996 150,000 12,460 - 1,540(5)
Anthony Vuolo..................... 1998 159,692 - 50,000 3,163(5)
Executive Vice President and 1997 150,000 - 81,000 2,019(5)
Chief 1996 150,000 - - 1,419(5)
Financial Officer (May 1997
through February 1999)(6)
</TABLE>
- - ----------------------
(1) Mr. Manning has been Vice Chairman since March 1998.
10
<PAGE>
(2) Dr. Margulies became an employee of the Company after the Company's
acquisition of CareAgents, Inc. on January 23, 1997. As such, only
compensation paid subsequent to January 23, 1997 is reflected above.
(3) These options were originally granted January 23, 1997 and were canceled
and replaced January 7, 1998.
(4) Includes Company matching contributions to the Porex Technologies Corp.
401(k) Savings Plan ("Porex 401(k) Plan") and life insurance premiums paid
on behalf of Mr. Hannah of $1,878 and $1,361, respectively, in the fiscal
year ended June 30, 1996, $3,795 and $2,106, respectively, in the fiscal
year ended June 30, 1997 and $1,577 and $2,106, respectively, in the fiscal
year ended June 30, 1998.
(5) Comprised of Company matching contributions to the Porex 401(k) Plan.
(6) On March 1, 1999, the Company announced the appointment of James R. Love as
Executive Vice President-Finance and Administration and Chief Financial
Officer and the appointment of Mr. Vuolo as Senior Vice President-Business
Development.
The following table presents information concerning the options
granted to the Named Executive Officers during the last fiscal year.
Option/SAR Grants in Last Fiscal Year
<TABLE>
<CAPTION>
Individual Grants
-----------------
% of Total
Number of Securities Options/SARs Exercise
Underlying Granted to or Base Grant Date
Options/SARs Employees Price Expiration Present Value
Name Granted (#) in Fiscal Year ($/Sh) Date ($)(4)
- - ---- -------------------- -------------- -------- ---------- -------------
<S> <C> <C> <C> <C> <C>
Paul C. Suthern.............. 10,000(1)(3) 0.40% 38.7500 7/1/12 145,856
184,000(1) 7.40% 36.8750 1/7/08 2,553,898
--------- ----- ---------
194,000 7.81% 2,699,754
David M. Margulies........... 272,728(2) 10.97% 36.8750 1/7/08 2,818,841
Charles A. Mele.............. 85,000(1) 3.42% 36.8750 1/7/08 1,179,790
Anthony Vuolo................ 50,000(1) 2.01% 36.8750 1/7/08 693,994
</TABLE>
____________
(1) These options vest and become exercisable at the rate of 20% per year,
commencing on the first anniversary of the date of grant and were granted
on the following dates: Mr. Suthern, 10,000 on July 1, 1997 and 184,000 on
January 7, 1998; Messrs. Vuolo and Mele, on January 7, 1998.
(2) These options vest and become exercisable at the rate of 40%, commencing on
the second anniversary of the date of grant and 20% on each subsequent
anniversary and were granted on January 7, 1998. This grant represents the
replacement of a grant of an option originally issued on January 23, 1997.
(3) These options were awarded to Mr. Suthern while serving as Vice Chairman of
the Board under the 1991 Director Stock Option Plan.
11
<PAGE>
(4) The estimated grant date present value reflected in the above table is
determined using the Black-Scholes model. The material assumptions and
adjustments incorporated in the Black-Scholes model in estimating the value
of the options reflected in the above table include the following: (i) the
respective option exercise price, specified above, equal to the fair market
value of the underlying stock on the date of grant; (ii) the exercise of
options within two years of the date that they become exercisable; (iii) a
risk-free interest rate of 6.3% per annum; and (iv) volatility of 0.2986
calculated using daily stock prices of the Company during the period from
the date of the purchase of shares of Common Stock from Merck & Co., Inc.
("Merck") by the Company and SN Investors on December 14, 1994 to June 30,
1998. The ultimate values of the options will depend on the future market
price of the Company's stock, which cannot be forecasted with reasonable
accuracy. The actual value, if any, an optionee will realize upon exercise
of an option will depend on the excess of the market value of the Company's
Common Stock over the exercise price on the date the option is exercised.
There is no assurance that the value realized by an optionee will be at or
near the value estimated by the Black-Scholes model or any other model
applied to value the options.
--------------------
No options to purchase Common Stock were exercised by the Named Executive
Officers during the fiscal year ended June 30, 1998.
The following table presents information concerning the fiscal year-end
value of options to purchase Common Stock held by the Named Executive Officers.
<TABLE>
<CAPTION>
Aggregated Option/SAR Exercises in Last Fiscal Year
and FY-End Option/SAR Values
Number of Securities Value of Unexercised
Underlying Unexercised In-the-Money Options/
Options/SARs at FY-End (#) SARs at FY-End ($)(1)
---------------------------- ----------------------------
Name Exercisable Unexercisable Exercisable Unexercisable
- - --------------------------------------- ----------- ------------- ----------- -------------
<S> <C> <C> <C> <C>
James V. Manning............................ 255,000 60,000 11,633,750 2,640,000
Paul C. Suthern............................. 234,000 266,000 8,944,500 6,471,500
David M. Margulies.......................... C 272,728 C 4,670,467
Ray E. Hannah............................... 72,000 32,000 2,990,500 592,000
Charles A. Mele............................. 109,000 241,000 3,983,250 4,848,625
Anthony Vuolo............................... 135,200 164,800 5,521,100 4,360,650
</TABLE>
- - -------------------
(1) Based upon the fiscal year-end closing price of the Common Stock of $54.00.
Amendment of Certain Stock Options
Ten Year Option Repricings
--------------------------
<TABLE>
<CAPTION>
Length of
Original
Market Exercise Option
Number of Value on Price at Term
Shares Date of Time of New Remaining
Repriced Repriced Repricing Exercise at Date of
Name Date (#) ($) ($) Price ($) Repricing
- - ------------------------ --------------- ------------ ---------- ----------- ---------- -----------
<S> <C> <C> <C> <C> <C> <C>
David M. Margulies January 7, 1998 272,728 36.875 47.500 36.875 9 years
Executive Vice
President-Chief
Scientist
</TABLE>
12
<PAGE>
DIRECTOR COMPENSATION
Those directors who are not officers or employees of the Company
received no cash compensation for serving as directors for the fiscal year ended
June 30, 1998. The Company's 1991 Director Stock Option Plan (the "Director
Plan") provides that on the first business day of each fiscal year of the
Company, each director who is not an officer or employee of the Company then in
office will automatically be granted an option to purchase 10,000 shares of
Common Stock. In addition, each director who is not an officer or employee of
the Company automatically receives an option to purchase 10,000 shares of Common
Stock at the time such director is first elected to the Board. The Director
Plan is administered by the Board or any executive officer or officers
designated by the Board. Non-employee directors (other than those directors who
serve on the Stock Option Committee) have also received in the past, options to
purchase Common Stock under the Company's 1989 Class A Stock Option Plan (the
"Class A Plan"), and the Company from time to time has granted options to
purchase Common Stock to certain of such directors outside the Company's stock
option plans on terms similar to those contained in the Class A Plan.
PLANS AND ARRANGEMENTS OF THE COMPANY
Pension Plan
Employees of the Company and certain of its subsidiaries who satisfy
certain age and service requirements are eligible to participate in the Pension
Plan for Employees of Porex Technologies Corp. (the "Pension Plan"), a defined
benefit plan. The Company bears the entire cost of the Pension Plan. The
Company's contributions to the Pension Plan are computed on an actuarial basis
in order to fund the defined retirement benefits.
Normal retirement benefits are payable monthly for life to a
participant upon retirement at his or her retirement date (i.e., age 65), and
are equal to 1/12 of the sum of (a) 0.6% of the participant's average annual
compensation for the five consecutive calendar years that the participant's
compensation was the highest during the ten consecutive years of service
immediately preceding retirement ("Final Average Compensation"), multiplied by
the participant's credited years of service up to a maximum of 35 years, and (b)
0.6% of the participant's Final Average Compensation in excess of the average
annual Social Security taxable wage base for the 35-year period ending with the
year the participant would reach normal retirement age, multiplied by the
participant's credited years of service up to a maximum of 35 years. A
participant becomes 100% vested in his or her accrued retirement benefit after
completion of five years of service or upon attainment of normal retirement at
age 65. Retirement benefits are not subject to any deduction for Social
Security or other offset amounts.
Under a defined benefit plan such as the Pension Plan, contributions
allocable to individual participants cannot be readily and accurately
calculated. The table below shows estimated annual retirement benefits for
executives at specified levels of remuneration and years of service. The
estimates assume that benefits commence at age 65 under a straight life annuity
form. The table discloses the benefits that an individual would receive at age
65 if he participated in the Pension Plan for 15, 20, 25, 30, 35 and 40 years.
13
<PAGE>
PENSION PLAN TABLE
<TABLE>
<CAPTION>
Years of Service
----------------------------------------------------------------------------------
Remuneration 15 20 25 30 35 40
------------ -- -- -- -- -- --
<S> <C> <C> <C> <C> <C> <C>
100,000 15,198 20,265 25,331 30,397 35,463 35,463
115,000 17,898 23,865 29,831 35,797 41,763 41,763
125,000 19,698 26,265 32,831 39,397 45,963 45,963
150,000 24,198 32,265 40,331 48,397 56,463 56,463
154,000 or more 24,918 33,225 41,531 49,837 58,143 58,143
</TABLE>
Ray E. Hannah, the only Named Executive Officer participating in the
Pension Plan, had accrued 30 credited years of service under the Pension Plan
and had annual remuneration covered by the Pension Plan of $160,000 as of
January 1, 1998. Sections 401(a)(17) and 415 of the Internal Revenue Code limit
the amount of compensation that may be considered in computing benefits under a
qualified retirement plan. For 1998, the maximum amount of compensation allowed
for use in calculating an individual's pension benefits under the Retirement
Plan was $160,000.
On May 1, 1998, the Company ceased all benefit accruals under the
Pension Plan. The Company terminated the Pension Plan on January 31, 1999. The
Company's obligation to Mr. Hannah is approximately $49,500 per annum.
14
<PAGE>
COMPARISON OF CUMULATIVE TOTAL SHAREHOLDER RETURN
AMONG SYNETIC, INC., NASDAQ U.S. COMPOSITE INDEX
AND COMPOSITE INDEXES
The following graphs compare the cumulative total shareholder return on the
Company's Common Stock for the period beginning June 30, 1993 and ending June
30, 1998 with: (a) in the case of Graph A, the cumulative total shareholder
return of the NASDAQ US Composite stock index and the Dow Jones Containers &
Packaging index and (b) in the case of Graph B, the cumulative total shareholder
return of the NASDAQ US Composite stock index and a composite index consisting
of the Dow Jones Containers & Packaging index and the Dow Jones Retailers and
Wholesalers Drug-Based index, weighted according to the distribution of the
Company's revenues in each time period between its plastics business and its
institutional pharmacy business (the "Dow Composite Index"). The comparison
assumes the investment of $100 on June 30, 1993 in Company Common Stock and in
each index and that dividends were reinvested on the ex-dividend date. The
Company is not included in the composite indexes.
[GRAPH A APPEARS HERE]
CUMULATIVE TOTAL RETURN
Based on reinvestment of $100 beginning June 30, 1993
<TABLE>
<CAPTION>
Measurement period Dow Jones Container
(Fiscal year Covered) Synetic, Inc. NASDAQ US Composite & Packaging Index
- - ----------------------- ------------- ------------------- -------------------
<S> <C> <C> <C>
Measurement PT -
06/30/93 $100 $100 $100
FYE 06/30/94 $108 $101 $103
FYE 06/30/95 $192 $135 $129
FYE 06/30/96 $290 $173 $129
FYE 06/30/97 $290 $210 $162
FYE 06/30/98 $447 $278 $165
</TABLE>
[GRAPH B APPEARS HERE]
CUMULATIVE TOTAL RETURN
Based on reinvestment of $100 beginning June 30, 1993
<TABLE>
<CAPTION>
Measurement period Dow Composite
(Fiscal year Covered) Synetic, Inc. NASDAQ US Composite (Container/Pharmacy)
- - ----------------------- ------------- ------------------- --------------------
<S> <C> <C> <C>
Measurement PT -
06/30/93 $100 $100 $100
FYE 06/30/94 $108 $101 $115
FYE 06/30/95 $192 $135 $156
FYE 06/30/96 $290 $173 $156
FYE 06/30/97 $290 $210 $196
FYE 06/30/98 $447 $278 $199
</TABLE>
15
<PAGE>
REPORT ON THE AMENDMENT OF CERTAIN STOCK OPTIONS
The exercise price of an option to purchase the Company's Common Stock
which had been originally granted to Dr. Margulies as an inducement to enter
into the employ of the Company in connection with the Company's acquisition of
CareAgents, Inc. on January 23, 1997 was amended on January 7, 1998. The new
exercise price applicable to such option is $36.875, the fair market value of
the Common Stock on such date. Such optionee was offered the opportunity to
amend his option provided that he agreed to a longer vesting schedule.
Stock options are intended to provide incentives to the Company's officers
and employees. The Stock Option Committee believes that such equity incentives
are a significant factor in the Company's ability to attract, retain and
motivate key employees who are critical to the Company's long term success.
With regard to certain stock options, the Stock Option Committee believed that,
at their original exercise price, the disparity between the exercise price of
such options and recent market prices for the Company's Common Stock did not
provide meaningful incentives to the employees holding these options. Inquiries
conducted indicated that other companies in the technology industry have been
confronted with this problem and have made similar adjustments in option prices
to motivate their employees. The Stock Option Committee approved the amendment
of such options as a means of ensuring that the optionee will continue to have
meaningful equity incentive to work toward the success of the Company. The
amendment was deemed by the Stock Option Committee to be in the best interests
of the Company and its stockholders.
Thomas R. Ferguson
Herman Sarkowsky
Albert M. Weis
16
<PAGE>
REPORT ON EXECUTIVE COMPENSATION
The Compensation Committee and the Stock Option Committee are composed of
three outside directors, Messrs. Ferguson, Sarkowsky and Weis. The Compensation
Committee is responsible for reviewing and approving compensation levels for the
Company's executive officers and reviewing and making recommendations to the
Board with respect to other matters relating to the compensation practices of
the Company. The Stock Option Committee is responsible for approving the grants
of options to purchase shares of Common Stock and general administration of the
Company's stock option plans.
The Company's compensation policies are intended to provide compensation
opportunities that will help attract, motivate and retain highly qualified
managers and executives and link their total compensation to increases in
shareholder value. The compensation of the Chief Executive Officer and the
other executive officers of the Company (other than Mr. Hannah) consists of base
salary and stock option grants. Stock options are generally exercisable in
annual installments over five years, reflecting the objective of the Board to
retain executives and to insure the linkage of executive compensation to
increases in shareholder value through stock appreciation. The Compensation
Committee intends to continue to use stock options as the key component of
executive compensation in order to provide long-term incentives that are aligned
to the interests of the stockholders of the Company. No specific formula is
used to determine stock option grants to any particular person (including the
Chief Executive Officer and the executive officers), but grants are generally
based upon factors such as the optionee's contribution toward Company
performance and expected contribution toward meeting long-term strategic goals
of the Company. Mr. Hannah's compensation consists of base salary, annual
incentive compensation and stock option grants. Mr. Hannah's incentive
compensation is based primarily upon the operating results of Porex and the
achievement of certain financial criteria established and communicated at the
beginning of the fiscal year.
For tax years beginning on or after January 1, 1994, Section 162(m) of the
Internal Revenue Code of 1986, as amended (the "Code"), limits the ability of a
publicly held corporation to deduct compensation in excess of $1 million paid to
certain executive officers. It is the policy of the Stock Option Committee and
the Compensation Committee to comply, where practicable, with Section 162(m) of
the Code so as to maximize the tax deductibility of compensation paid to its top
executive officers. Accordingly, the Company's stock option plans under which
awards are made to the Company's officers and directors are currently designed
to ensure that compensation attributable to options granted thereunder will be
tax deductible by the Company. It is possible, however, that options granted
under the Company's option plans prior to such compliance to certain individuals
who may subsequently become subject to Section 162(m) may not be fully
deductible by the Company. The Compensation Committee does not, however,
anticipate that the compensation from the Company to any executive officer
during fiscal year ending June 30, 1999 will exceed the limits on deductibility
for such period.
Thomas R. Ferguson
Herman Sarkowsky
Albert M. Weis
17
<PAGE>
CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
Purchase and Sale Agreement. On December 14, 1994, pursuant to the
Purchase and Sale Agreement dated as of May 24, 1994 between the Company and
Merck (the "Purchase and Sale Agreement"), the Company purchased 5,268,463
shares of the Company's Common Stock (the "Purchase") from Merck for an
aggregate purchase price of $37,764,019. At the time of the purchase by the
Company, SN Investors purchased 5,061,857 shares of the Company's Common Stock
(the "Wygod Shares" and, collectively with the shares purchased by the Company,
the "Shares") from Merck for an aggregate purchase price of $36,283,079. The
purchase by SN Investors was made pursuant to an assignment by the Company to
Mr. Wygod of the right to purchase the Wygod Shares pursuant to the Investment
Agreement between Mr. Wygod and the Company, dated as of September 13, 1994 (the
"Investment Agreement"). Mr. Wygod, as permitted under the Investment
Agreement, further assigned to SN Investors his right to purchase the Wygod
Shares. The Investment Agreement governs the terms and conditions under which
the Wygod Shares will be held by Mr. Wygod and his permitted assignees and
transferees. See "-Investment Agreement".
In the Purchase and Sale Agreement, the Company agreed, until May 24, 1999,
to be bound by the restrictions contained in the Consulting Agreement described
below under "-Consulting Agreement", provided that such restrictions shall be of
no further force and effect in the event of the death of Mr. Wygod, or if Mr.
Wygod ceases to be a director of the Company or any subsidiary of the Company,
ceases to have any ownership interest in the Company (provided that, if the
Company is a public company he may have up to a 1% equity interest in the
Company), and is not a principal, agent or employee of or consultant to the
Company or any subsidiary of the Company, or is not otherwise rendering any
services to the Company or any subsidiary of the Company.
Investment Agreement. In the Investment Agreement, the Company assigned
the rights and obligations to purchase the Wygod Shares to Mr. Wygod. The
Investment Agreement governs the terms and conditions under which the Wygod
Shares are held by Mr. Wygod and his permitted assignees and transferees. Mr.
Wygod, as permitted under the Investment Agreement, assigned such rights and
obligations to SN Investors. Pursuant to the Investment Agreement, SN Investors
was (1) required to be a limited partnership in which Mr. Wygod or an entity
controlled by Mr. Wygod is the general partner and one or more of his family
trusts and/or partnerships (collectively, the "Wygod Entities") and/or
independent third parties are limited partners and (2) required to agree to be
bound by all of the restrictions and obligations applicable to Mr. Wygod under
the Investment Agreement. The Investment Agreement required the initial
investment of the Wygod Entities in SN Investors to be at least $20,000,000 (on
a cost basis) (the "Wygod Investment").
The Investment Agreement describes certain restrictions regarding the
voting and disposition of the Wygod Shares. The Investment Agreement provides
that these restrictions no longer apply after the occurrence of a Change of
Control of the Company (as defined in the Investment Agreement). The definition
of "Change of Control" under the Investment Agreement includes, among other
things, the issuance, following the closing of the Purchase, by the Company of
shares of Common Stock constituting in the aggregate more than 50% of the shares
of Common Stock outstanding as of immediately following the closing of the
Purchase. Immediately following the Purchase, 12,509,709 shares of Common Stock
were outstanding. As of March 3, 1999, the Company had issued 7,827,434 shares
of Common Stock since the closing of the Purchase. Accordingly, there has been
a "Change of Control" as defined in the Investment Agreement and the
restrictions on the voting and disposition of the Wygod Shares contained in the
Investment Agreement no longer apply.
The Investment Agreement also provides certain demand registration rights
to Mr. Wygod at Mr. Wygod's expense that are assignable to any permitted
transferee of the Wygod Shares; provided that, in no event is the Company
required to file in the aggregate more than two registration statements in
connection therewith. Mr. Wygod has not assigned such registration rights to SN
Investors. While Mr. Wygod currently intends to assign such registration rights
to SN Investors in the event the General Partner determines to sell or otherwise
transfer the Wygod Shares under circumstances in which registration would be
required, Mr. Wygod is under no obligation to do so.
Consulting Agreement. In the Consulting Agreement, dated as of May 24,
1994 (the "Consulting Agreement"), by and among Mr. Wygod, Merck and Medco, Mr.
Wygod has agreed that, until May 24, 1999, absent Merck's prior written
approval, he will not (as principal, agent, employee, consultant or otherwise)
directly or
18
<PAGE>
indirectly engage in activities with, nor render services to, any business
engaged or about to become engaged in a Competitive Business (as defined in the
Consulting Agreement). A "Competitive Business" is defined in the Consulting
Agreement as: (a) the pharmaceutical business of Merck and its affiliates
(unless such business is subsequently disposed of and Mr. Wygod did not have
material involvement in such business during the two-year period preceding May
24, 1994), (b) the business, as of either November 18, 1993 or May 24, 1994, of
Medco and its subsidiaries (unless such business is subsequently disposed of and
Mr. Wygod did not have material involvement in such business during the two-year
period preceding May 24, 1994), other than the business of Porex and the other
plastic businesses of the Company as conducted as of May 24, 1994, or (c) any
other then-current business of Merck and its affiliates as to which Mr. Wygod
became materially involved following November 18, 1993; provided, however, that
the Consulting Agreement permits Mr. Wygod to have a 1% or less equity interest
in a Competitive Business that is a public corporation. In addition, the
Consulting Agreement provides that, until May 24, 1999, Mr. Wygod will not,
directly or indirectly: (i) solicit or contact any customer or prospective
customer of Medco and/or any of its affiliates as to matters that relate to a
Competitive Business in which Medco or its affiliates is then engaged or which
is in any way inconsistent or interferes therewith; (ii) induce, or attempt to
induce, any employees or agents or consultants of Medco and/or its affiliates to
do anything from which Mr. Wygod is restricted by reason of the Consulting
Agreement; or (iii) offer or aid others to offer employment to any employees of
Medco or its affiliates.
On February 18, 1999, Merck and Merck-Medco Managed Care, L.L.C. ("Merck-
Medco") filed a complaint against Mr. Wygod, as well as Synetic and certain
officers of Synetic, in the Superior Court of New Jersey. The complaint asserts
that Mr. Wygod is in violation of certain non-competition provisions of the
Consulting Agreement and seeks, among other things, to enjoin him, as well as
Synetic and certain officers of Synetic, from conducting Synetic's healthcare
communications business. Synetic believes that Merck's and Merck-Medco's
positions are without merit. Synetic intends to vigorously defend against
Merck's and Merck-Medco's complaint and assert appropriate claims for any
damages caused by Merck and Merck-Medco.
Other. The Company was reimbursed approximately $137,109 by a corporation
controlled by Mr. Wygod for the partial use of the Company's office facilities
and for services rendered by Company employees during the fiscal year ended June
30, 1998.
PROPOSAL TWO:
RATIFICATION OF INDEPENDENT AUDITORS
Upon recommendation of the Audit Committee, the Board has appointed Arthur
Andersen LLP as its independent auditors for the fiscal year ending June 30,
1999. A resolution will be submitted to stockholders at the Meeting to ratify
their appointment. The affirmative vote of the holders of a majority of the
shares of Common Stock present at the Meeting with respect to Proposal Two will
be required to approve this resolution. The Board recommends a vote FOR this
resolution. The proxy will be voted in accordance with the directions thereon
with respect to Proposal Two or, if no directions are indicated, FOR
ratification of the appointment of Arthur Andersen LLP. Although stockholder
approval of the Board's appointment of Arthur Andersen LLP is not required by
law, the Board believes that it is advisable to give stockholders an opportunity
to ratify this selection. If this proposal is not approved at the Annual
Meeting, the Board will reconsider its selection of Arthur Andersen LLP.
A representative of Arthur Andersen LLP is expected to be present at the
Meeting. The representative will be afforded an opportunity to make a statement
and will be available to respond to questions by stockholders. If the
resolution ratifying the appointment of Arthur Andersen LLP as independent
auditors is approved by the stockholders, the Board nevertheless retains the
discretion to select different auditors in the future, should the Board then
deem such selection to be in the Company's best interest. Any such selection
need not be submitted to a vote of stockholders.
19
<PAGE>
STOCKHOLDER PROPOSALS FOR 1999 ANNUAL MEETING
Stockholders are entitled to submit proposals on matters appropriate for
stockholder action consistent with regulations of the Commission. Should a
stockholder intend to present a proposal at the Company's 1999 Annual Meeting,
which will be held after the end of the Company's fiscal year ending June 30,
1999, it must be received by the Secretary of the Company, 669 River Drive,
Elmwood Park, New Jersey 07407-1361, not later than November 12, 1999 to be
considered for inclusion in the Company's Proxy Statement and form of proxy for
that meeting. If the date of the 1999 Annual Meeting of the Company is changed
by more than 30 days from the date of the 1998 Annual Meeting, then this change
will be disclosed in the earliest possible Form 10-Q of the Company and any
stockholder proposal to be presented at the 1999 Annual Meeting must be received
by the Company a reasonable time before the Company mails its proxy materials
for the 1999 Annual Meeting to be considered for inclusion in the Company's
Proxy Statement and form of proxy for that meeting. Any proxy received by the
Company may confer discretionary authority to vote on any shareholder proposal
not received by the Company by February 16, 2000.
MISCELLANEOUS
Where information contained in this Proxy Statement rests particularly
within the knowledge of a person other than the Company, the Company has relied
upon information furnished by such person or contained in filings made by such
person with the Commission.
By Order of the Board of Directors
Charles A. Mele
Secretary
20
<PAGE>
REVOCABLE PROXY
SYNETIC, INC.
[X] PLEASE MARK VOTES
AS IN THIS EXAMPLES
ANNUAL MEETING OF STOCKHOLDERS
APRIL 16, 1999
The undersigned hereby appoints Victor L. Marrero, Charles A. Mele and Paul
C. Suthern, and each of them, as the true and lawful agents and proxies of the
undersigned, with full power of substitution, to represent the undersigned and
to vote all shares of stock which the undersigned is entitled in any capacity to
vote at the Annual Meeting of Stockholders of SYNETIC, INC. (the "Company") to
be held at the St. Regis Hotel, Two East 55th Street, New York, New York 10022
at 9:30 A.M., local time, on April 16, 1999 and at any and all adjournments or
postponements thereof, on the matters set forth below, and, in their discretion,
upon all matters incident to the conduct of the Annual Meeting and upon such
other matters as may properly be brought before the meeting. This Proxy revokes
all prior proxies given by the undersigned. This Proxy, when properly executed,
will be voted in the manner directed herein by the undersigned stockholder. If
no direction is made, this Proxy will be voted FOR the election of each of the
nominees for director listed hereon and FOR Proposal 2.
Please be sure to sign and date
this Proxy in the box below Date
---------------------------
------------------------------------- -----------------------------------
Stockholder sign above Co-holder (if any) sign above
1. The election as directors of all nominees listed (except as marked to the
contrary below) to serve a term of one year:
FOR WITHHOLD FOR ALL EXCEPT
[_] [_] [_]
THOMAS R. FERGUSON, MERVYN L. GOLDSTEIN, M.D., RAY E. HANNAH, ROGER H.
LICHT, JAMES V. MANNING, BERNARD A. MARDEN, CHARLES A. MELE, HERMAN
SARKOWSKY, PAUL C. SUTHERN, ALBERT M. WEIS AND MARTIN J. WYGOD.
INSTRUCTION: TO WITHHOLD AUTHORITY TO VOTE FOR ANY INDIVIDUAL NOMINEE, MARK "FOR
ALL EXCEPT" AND WRITE THAT NOMINEE'S NAME IN THE SPACE PROVIDED BELOW.
- - --------------------------------------------------------------------------------
1. Ratification of the appointment of Arthur Andersen LLP as independent public
auditors of the Company for the fiscal year ending June 30, 1999.
FOR AGAINST ABSTAIN
[_] [_] [_]
THIS PROXY IS SOLICITED BY THE BOARD OF DIRECTORS OF THE COMPANY. THE
DIRECTORS RECOMMEND A VOTE FOR ELECTION OF ALL NOMINEES AND FOR PROPOSAL 2.
RECEIPT OF NOTICE OF SAID MEETING AND OF THE PROXY STATEMENT AND ANNUAL
REPORT OF SYNETIC, INC. IS HEREBY ACKNOWLEDGED.
Please sign the Proxy exactly as your name appears hereon. Joint owners
should each sign. Trustees, executors, administrators and others signing in a
representative capacity should indicate in which capacity they are signing. An
authorized officer may sign on behalf of a corporation and should indicate the
name of the corporation and his capacity.
- DETACH ABOVE CARD, SIGN, DATE AND MAIL IN POSTAGE PAID ENVELOPE PROVIDED. -
SYNETIC, INC.
- - --------------------------------------------------------------------------------
PLEASE ACT PROMPTLY
SIGN, DATE & MAIL YOUR PROXY CARD TODAY
- - --------------------------------------------------------------------------------
